BioSig Technologies Inc (NASDAQ:BSGM) announced Friday that the company and its NeuroClear Technologies division signed a new research agreement with the University of Minnesota.
Under the terms of the agreement, BioSig said it intends to launch a program to develop novel therapies to treat sympathetic nervous system disease.
Due to launch in the fourth quarter of 2020, the program studies are expected to form a foundation for developing a new platform technology to address disorders of the autonomic nervous system, the company said.
READ: BioSig Technologies announces the first commercial sale of its PURE EP Systems
NeuroClear plans to develop new intellectual properties (IP) and products, including new hardware, software, and algorithmic solutions, with the support of a tier 1 US-based manufacturing partner.
Then it plans to take the IP and products through US Food and Drug Administration to approval, manufacturing, and commercialization.
BioSig said the R&D program will be run under the leadership of Richard Bianco, a professor and director of Experimental Surgical Services (ESS) at the Department of Surgery in the University of Minnesota Medical School.
Also included is professor John Osborn of the Department of Surgery and director of the Minnesota Consortium for Autonomic Neuromodulation (MCAN) in the University of Minnesota Medical School, and Barry Keenan, vice president of engineering at NeuroClear.
“Our mission is to lead through innovation in bioelectronic medicine, and we are most impressed with the cutting-edge research work led by John and his colleagues,” said BioSig CEO Kenneth Londoner in a statement.
“Our team made tremendous progress in the past twelve months, having identified several lucrative opportunities, onboarded a leading manufacturing partner, and developed a scientific proposal to drive this program forward. We are thrilled to begin this new chapter and look forward to reporting on our progress.”
BioSig is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham
